[ad_1]
HIG Capital (“HIG”), a leading global alternative investment company with more than US$45 billion in equity capital under management, is pleased to announce that one of its “Or “company”), a leading supplier of generic drugs and specialty drugs in the United States.
Rising Pharmaceuticals develops and sells generic drugs and specialty branded drugs in various therapeutic categories. The company adopts a light asset model and a fully outsourced third-party network to provide powerful functions across multiple dosage forms. Rising Pharmaceuticals has a diversified portfolio of more than 125 products and the ability to quickly commercialize complex molecules, and has a strategic positioning in the US pharmaceutical market. HIG has partnered with Rising Pharmaceuticals CEO Vimal Kavuru to continue the company’s strong growth record and support new initiatives such as mergers and acquisitions and new product launches.
“We are very happy to work with Vimal Kavuru and Rising Pharmaceutical’s excellent management team,” said Mike Gallagher, HIG’s managing director. “As a partner, we look forward to supporting Vimal and his team in further development on the basis of Rising Pharmaceutical’s great success. Seeing major opportunities in the broader U.S. generic drug industry and the company’s track record in identifying, developing and launching complex pharmaceutical products should create an exciting new chapter for Rising Pharmaceuticals.”
“We are keen to enter…
The full story can be found on Benzinga.com
[ad_2]
Source link
